900186-72-3

Basic information

• Product Name: (3R,3aS,4S,4aS,7R,9aR)-3-Methyl-7-nitro-1-oxo-N,N-diphenyl-1,3,3a,4,4a,5,6,7,8,9a-decahydronaphtho[2,3-c]furan-4-carboxamide
• Synonyms: (3R,3aS,4S,4aS,7R,9aR)-1,3,3a,4,4a,5,6,7,8,9a-Decahydro-3-methyl-7-nitro-1-oxo-N,N-diphenylnaphtho[2,3-c]furan-4-carboxamide;3-Methyl-7-Nitro-1-oxo-N,N-Dimethyl Decahydro [2,3-C]furan-4-carboxamide;(R,E)-5-(diphenylamino)-5-oxopent-3-en-2-yl (E)-3-(5-nitrocyclohex-1-en-1-yl)acrylate;(3R,3aS,4S,4aS,7R,9aR)-3-Methyl-7-nitro-1-oxo-N,N-diphenyl-1,3,3a,4,4a,5,6,7,8,9a-decahydronaphtho[2,3-c]furan-4-carboxamide
• CAS NO: 900186-72-3
• Molecular Formula: C26H26N2O5
• Molecular Weight: 446.49504
• Product Categories: VORAPAXAR
• Mol File: 900186-72-3.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 725.9±60.0 °C(Predicted)
• Appearance: /
• Density: 1.32±0.1 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 7.47±0.60(Predicted)
• CAS DataBase Reference: (3R,3aS,4S,4aS,7R,9aR)-3-Methyl-7-nitro-1-oxo-N,N-diphenyl-1,3,3a,4,4a,5,6,7,8,9a-decahydronaphtho[2,3-c]furan-4-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: (3R,3aS,4S,4aS,7R,9aR)-3-Methyl-7-nitro-1-oxo-N,N-diphenyl-1,3,3a,4,4a,5,6,7,8,9a-decahydronaphtho[2,3-c]furan-4-carboxamide(900186-72-3)
• EPA Substance Registry System: (3R,3aS,4S,4aS,7R,9aR)-3-Methyl-7-nitro-1-oxo-N,N-diphenyl-1,3,3a,4,4a,5,6,7,8,9a-decahydronaphtho[2,3-c]furan-4-carboxamide(900186-72-3)

Safety Data

• Hazardous Substances Data: 900186-72-3(Hazardous Substances Data)

Usage

Uses

S,?4S,?4aS,?7R,?9aR)?-1,?3,?3a,?4,?4a,?5,?6,?7,?8,?9a-?Decahydro-?3-?methyl-?7-?nitro-?1-?oxo-?N,?N-?diphenyl-?naphtho[2,?3-?c]?furan-?4-?carboxamide is a related compound of Himbacine (H456343), an alkaloid muscarinic receptor antagonist.

Upstream product

• 1017854-11-3 C₂₆H₂₆N₂O₅ 
• 900186-73-4 C₂₆H₂₆N₂O₅ 
• 900186-73-4 C₂₆H₂₆N₂O₅ 

Relevant articles and documents

Thrombin Receptor Antagonists Based On The Modified Tricyclic Unit Of Himbacine

Multiple stereoisomers of the heterocyclic-substituted tricyclics of the formula: or a pharmaceutically acceptable salt, solvate, or ester of said compound wherein R and the stereochemistry are illustrated in the structural formulas herein are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.